CompletedPhase 2NCT01851200
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Studying Non-seminomatous germ cell tumor of testis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Michelangelo
- Principal Investigator
- Alessandro M Gianni, MD, MDFondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Intervention
- Brentuximab Vedotin(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2013 – 2017
Study locations (1)
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Mi, Italy
Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Millennium Pharmaceuticals, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01851200 on ClinicalTrials.gov